For the quarter ended March 2026, Regeneron (REGN Quick QuoteREGN - Free Report) reported revenue of $3.61 billion, up 19% over the same period last year. EPS came in at $9.47, compared to $8.22 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $3.44 billion, representing a surprise of +4.88%. The company delivered an EPS surprise of +11.18%, with the consensus EPS estimate being $8.52.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Regeneron performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- EYLEA- United States: $473.1 million compared to the $435.8 million average estimate based on five analysts.
• Revenues- EYLEA HD- United States: $468.4 million versus the five-analyst average estimate of $467.82 million.
• Revenues- Eylea (Aflibercept)(EYLEA HD and EYLEA)- US: $941.5 million versus the five-analyst average estimate of $903.42 million. The reported number represents a year-over-year change of -9.7%.
• Revenues- Libtayo- US: $286.1 million versus the four-analyst average estimate of $244 million. The reported number represents a year-over-year change of +48.6%.
• Revenues- Collaboration: $1.9 billion versus $1.86 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +24.1% change.
• Revenues- Other Revenue: $171.2 million versus the six-analyst average estimate of $145 million. The reported number represents a year-over-year change of +109%.
• Revenues- Net product sales: $1.53 billion versus $1.44 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +8.4% change.
• Revenues- Total Bayer collaboration revenue: $287 million versus the five-analyst average estimate of $308.34 million. The reported number represents a year-over-year change of -16.6%.
• Revenues- Total Sanofi collaboration revenue: $1.61 billion versus the five-analyst average estimate of $1.55 billion. The reported number represents a year-over-year change of +35.7%.
• Revenues- Libtayo- Total: $438.2 million compared to the $360.53 million average estimate based on four analysts. The reported number represents a change of +53.7% year over year.
• Revenues- Eylea (Aflibercept)(EYLEA HD and EYLEA)- Total: $1.67 billion versus $1.72 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -12.1% change.
• Revenues- Dupixent (dupilumab)- Total: $4.88 billion compared to the $4.57 billion average estimate based on two analysts. The reported number represents a change of +33.1% year over year.

View all Key Company Metrics for Regeneron here>>>

Shares of Regeneron have returned -5.3% over the past month versus the Zacks S&P 500 composite's +12.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.